Headlines about ABIOMED (NASDAQ:ABMD) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. ABIOMED earned a news impact score of 0.05 on Accern’s scale. Accern also assigned media coverage about the medical equipment provider an impact score of 44.6828702782984 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Shares of ABIOMED (ABMD) traded up $6.03 on Tuesday, hitting $294.01. 538,444 shares of the stock traded hands, compared to its average volume of 422,486. ABIOMED has a 52 week low of $117.36 and a 52 week high of $304.28. The firm has a market capitalization of $12,975.62, a P/E ratio of 148.49, a price-to-earnings-growth ratio of 4.06 and a beta of 0.25.

How to Become a New Pot Stock Millionaire

ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.20. ABIOMED had a net margin of 16.58% and a return on equity of 15.54%. The company had revenue of $154.00 million during the quarter, compared to the consensus estimate of $154.00 million. During the same quarter in the previous year, the company posted $0.34 earnings per share. The company’s revenue for the quarter was up 34.9% compared to the same quarter last year. equities analysts forecast that ABIOMED will post 2.29 earnings per share for the current fiscal year.

ABMD has been the subject of several recent research reports. BidaskClub lowered shares of ABIOMED from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. Jefferies Group boosted their price target on shares of ABIOMED from $208.00 to $220.00 and gave the company a “buy” rating in a report on Thursday, December 21st. Zacks Investment Research raised shares of ABIOMED from a “hold” rating to a “buy” rating and set a $213.00 price target for the company in a report on Friday, December 29th. Piper Jaffray Companies reissued a “buy” rating on shares of ABIOMED in a report on Thursday, January 4th. Finally, Leerink Swann boosted their price target on shares of ABIOMED from $200.00 to $265.00 and gave the company an “outperform” rating in a report on Friday, January 19th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. ABIOMED has a consensus rating of “Buy” and an average price target of $288.86.

In related news, VP Andrew J. Greenfield sold 20,000 shares of the company’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $270.36, for a total value of $5,407,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 7.00% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was first published by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-abiomed-abmd-share-price/1950846.html.


ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Insider Buying and Selling by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.